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Convulsive status epilepticus (CSE), defined as a generalized tonic-clonic seizure lasting more 
than 5 minutes, is a life-threatening condition, which needs to be promptly recognized to 
reduce the risk of long-term consequences including increased mortality and morbidity [1]. 
Its treatment follows a stepwise approach, with benzodiazepines representing the first-line 
treatment. In benzodiazepine-resistant CSE, intravenous antiepileptic drugs (AEDs) are 
administered.  
In a recent systematic review of the literature we estimated the comparative efficacy and 
safety of intravenous AEDs in adults with benzodiazepine-resistant CSE; on the basis of the 
network meta-analysis (NMA) of the results of five trials, we concluded that high-dose 
phenobarbital (PHB) is effective in controlling CSE and preventing seizure recurrence, 
whereas lacosamide (LCM) and valproate (VPA) could be better tolerated options [2]. 
However, these findings were mostly driven by the very high-dose of PHB used in the 
included trial [3]. 
Recently, the results of the Established Status Epilepticus Treatment Trial (ESETT) have been 
published [4]. This large, high-quality, randomized controlled trial (RCT) compared 
levetiracetam (LEV), fosphenytoin (fosPHT) and VPA in patients with benzodiazepine-
resistant CSE. These three drugs, infused over a period of 10 minutes, showed similar 
effectiveness and incidence of adverse events.  
Taking into account the relevance of the ESETT results, we incorporated them into the 
previous NMA. In addition, we removed two RCTs from the initial analysis, one comparing 
diazepam versus VPA [5] and one comparing very high-dose PHB (20 mg/Kg as loading dose) 
versus VPA [3] in order to compare only AEDs (i.e., excluding benzodiazepines) used at 
dosages within the range proposed by the American Epilepsy guidelines and usually 
administered in clinical practice [6]. Efficacy outcomes were CSE cessation within 1 h from 
drug administration and seizure freedom at 24 h. Safety outcomes included respiratory 
depression and hypotension. Effect sizes were estimated by NMA within a frequentist 
framework. The hierarchy of competing interventions was established using the surface 
under the cumulative ranking curve (SUCRA) and mean ranks.  
Four RCTs were considered, involving 594 patients. Included interventions were: VPA (20-
40 mg/kg), PHT (20 mg/kg), fosPHT (20 mgPE/Kg), LCM 400 mg, and LEV (20-60 mg/kg). No 
difference was found for the occurrence of CSE cessation, seizure freedom at 24 hours, 
respiratory depression and hypotension. According to SUCRA, VPA had the greatest 
 
 
probabilities of being best in the achievement of CSE control and seizure freedom, and the 
lowest probability of respiratory depression; LCM had the lowest probability of hypotension 
(Table 1). 
Network meta-analyses cannot replace direct head-to-head comparative trials but may 
provide some evidence about the relative efficacy and safety of drugs [Brigo et al., 2019a]. 
Although no difference was found in any direct comparison between the five AEDs assed, 
this updated NMA could offer useful clinical information about the hierarchy of competing 
interventions. Results should be read with some caution due to the risk of clinical 
heterogeneity (ESETT included both adults and children; 61% of patients were aged ≥18 
years). Additional efforts are required to estimate the comparative effectiveness of 
traditional versus newer AEDs, for which increasing evidence exists about their role in the 
treatment of status epilepticus [7,8]. 
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Table 1. Ranking according to SUCRA and mean rank for the efficacy and safety outcomes 
 
a) Status epilepticus cessation 
Treatment SUCRA Mean rank 
PHT 55.6 2.8 
VPA 59.9 2.6 
LEV 53.7 2.9 
LCM 34.5 3.6 
fosPHT 46.2 3.2 
 
b) Seizure freedom at 24 hours 
Treatment SUCRA Mean rank 
PHT 69.0 1.9 
VPA 69.7 1.9 
LEV 25.5 3.2 
LCM 35.9 2.9 
 
c) Respiratory depression 
Treatment SUCRA Mean rank 
PHT 21.4 4.1 
VPA 70.8 2.2 
LEV 66.3 2.3 
LCM 66.0 2.4 
fosPHT 25.5 4.0 
 
d) Hypotension 
Treatment SUCRA Mean rank 
PHT 5.8 4.8 
VPA 55.9 2.8 
LEV 77.5 1.9 
LCM 77.8 1.9 
fosPHT 32.9 3.7 
 
Abbreviations: fosPHT=fosphenytoin, LCM=lacosamide, LEV=levetiracetam, PHT=phenytoin, 
SUCRA=surface under the cumulative ranking curve, VPA=valproic acid. Higher SUCRA values 
correspond to higher probabilities of better efficacy/tolerability. 
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al., 2007  
India Continuous 
convulsive seizure > 
5 min without 
recovery of 
consciousness 
Adults > 18 
years 
DZP 0.2 mg/kg at 
2 mg/min IV, max 
20 mg 
PHT 20 mg/kg, 
max rate: 50 
mg/min  
VPA 20 mg/kg 
administered 
at 40 mg/min 
 
Chakravarthi 
et al., 2015   
India ≥2 convulsive 
seizures without 




convulsive seizure > 
5 min  
Adolescents 
and adults 
LZP 0.1 mg/kg at 
1 mg/min IV 







max rate: 50 
mg/min 
LEV 20 mg/kg 
administered 








Misra et al., 
2017  





convulsions > 5 
min. Subtle 
convulsive SE: 
coma and ictal 




Adults > 18 
years 
LZP 4 mg in 2-4 
min  IV(repeated 
once if seizures 
not controlled) 
VPA 30 mg/Kg 
at 100 
mg/min 
LCM 400 mg 
at 60 mg/min 
 
Kapur et al., 
2019 
USA Convulsive SE: 
persistent or 
recurrent 
convulsions in the 
emergency 
department at least 
5 min after the last 
dose of 
benzodiazepines 
and no more than 
30 min after the 
last dose of 
benzodiazepines 




weight ≥32 kg: 
DZP 10 mg (IV or 
rectally), LZP 4 
mg IV, or 




weight <32 kg: 
DZP 0.3 mg/kg (IV 
or rectally), LZP  





or 0.2 mg/kg IV 
(administered 






















SE: status epilepticus 
VPA: valproate 
  
Table 2: Clinical characteristics of patients  
 
  















Etiology of SE 
Agarwal et 












CNS infections 24% 
Primary generalized seizure 12% 
Stroke 4% 













CNS infections 20% 
Primary generalized seizure 16% 
Stroke 4% 
Extradural hematoma 4% 
Juvenile myoclonic epilepsy 4% 
Brain metastasis 4% 
 
Chakravarthi 
et al., 2015  
PHT 
group 






63.6% Convulsive SE 100% 72.05±48.57 
min 
Idiopathic 31.8% 
Acute symptomatic 13.6% 
Remote symptomatic 54.5% 
LEV 
group 





77.2% Convulsive SE 100% 55.91±73.75 
min 
Idiopathic 27.3% 
Acute symptomatic 45.5% 
Remote symptomatic 27.3% 










convulsive SE 90.9% 
















convulsive SE 97% 





CNS infections 33.3% 
Stroke 18.2% 
Others 48.5% 































     
 
AED: antiepileptic drugs 
CNS: central nervous system 
h: hour(s) 
min: minute(s) 
NR: not explicitly reported 
SD: standard deviation 
SE: status epilepticus 
  



































unlikely to be 
influenced by lack 
of blinding) 













depending on the 
order of 
recruitment) 









unlikely to be 
influenced by lack 
of blinding) 








Misra et al., 
2017  













unlikely to be 
influenced by lack 
of blinding) 








Kapur et al., 
2019  






Low risk  








unlikely to be 
influenced by lack 
of blinding) 






Table 4: Ranking according to SUCRA for the efficacy and safety outcomes 
a) Status epilepticus cessation 
 
 
b) Seizure freedom at 24 hours 
 
 









Figure 1. Network of treatment comparisons for efficacy and safety 
a) Status epilepticus cessation    b) Seizure freedom at 24 hours 
 
c) Respiratory depression       d) Hypotension 
       
 
 
The width of the lines is proportional to the inverse of the variance of the comparison 
treatment effect and the size of every circle is proportional to the number of randomly 
assigned participants.  




Figure 2. Interval plots for the efficacy and safety outcomes 
a) Status epilepticus cessation 
 
 
b) Seizure freedom at 24 hours 
 
  







Abbreviations: CI=confidence interval, fosPHT=fosphenytoin, LCM=lacosamide, 
LEV=levetiracetam, PHT=phenytoin, VPA=valproic acid. 
 
 
